Boehringer in HCV partnership
14.03.2013 - Boehringer Ingelheim and US firm Presidio Pharmaceuticals will combine their drugs against Hepatitis C.
The firms said they entered a non-exclusive collaboration for a 12-week Phase IIa trial of an oral combination treatment for patients with chronic hepatitis C virus (HCV) infection starting in Q2/2013. San Francisco-based Presidio will contribute its second-generation NS5A inhibitor PPI-668 whilst Boehringer Ingelheim will chip in its HCV protease inhibitor faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor BI207127. The combination will be tested with or without ribavirin.
"The study will assess the potential of this three-drug oral regimen to achieve high rates of sustained viral clearance in hepatitis C patients, with good tolerance.", said Dr Nathaniel Brown, DMO of Presidio, who will have primary responsibility for the trial. Both companies will retain all rights to their compounds. Data from the trials are anticipated in Q4/2013.
The current standard treatment for patients with hepatitis C genotype-1 infection is pegylated interferon-alfa (ribavirin) and an HCV protease inhibitor.